ESC Premium Access

Tips for getting out of trouble in the EP and device labs

Event: ESC Congress 2018
Topic: Treatment
Session type: Clinical Cases
Date: 28 August 2018
Time: 14:30 - 15:45

Session

6 presentations in this session

Bipolar radiofrequency ablation of ventricular tachycardia delivered between left ventricular endocardium and adjacent right atrial sites.

Speaker: Associate Professor P. Futyma (Rzeszow, PL)
Thumbnail

Catheter ablation of the epicardial electrical substrate in a patient with Brugada Syndrome and recurrent ICD shocks.

Speaker: Doctor J. Du Fay De Lavallaz (Basel, CH)
Thumbnail

Ventricular tachycardia ablation in prior myocarditis.

Speaker: Doctor S. Conti (Palermo, IT)
Thumbnail

Asymptomatic Long QT syndrome 3 - ICD implantation appropriate or not?

Speaker: Doctor K. Koranne (Mason City, US)
Thumbnail

Transseptal puncture via the right jugular vein approach and remote magnetic navigation ablation of left atrial tachycardia in patient with inferior vena cava interruption.

Speaker: Mr D. Losik (Novosibirsk, RU)
Thumbnail

Challenging management of atrial fibrillation in an unexpectedly complex grown up congenital heart disease. The role of mutimodality imaging.

Speaker: Doctor A. Baritussio (Padua, IT)
Thumbnail

6 speakers from this session

Associate Professor Piotr Futyma

Medical College, University of Rzeszow and St. Joseph's Heart Rhythm Center, Rzeszow (Poland)
5 presentations
0 follower

Doctor Jeanne Du Fay De Lavallaz

University Hospital Basel, Basel (Switzerland)
1 presentation
0 follower

Doctor Sergio Conti

ARNAS Civico hospital, Palermo (Italy)
1 presentation
0 follower

Doctor Ketan Koranne

Mason City Clinic and Mercy Hospital North Iowa, Mason City (United States of America)
1 presentation
0 follower

Mr Denis Losik

National Medical Research Center named after E.N.Meshalkin, Novosibirsk (Russian Federation)
2 presentations
0 follower

Doctor Anna Baritussio

University of Padova, Padua (Italy)
9 presentations
6 followers

This platform is supported by

logo Novo Nordisk